Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)‘s stock had its “ourperform” rating reaffirmed by investment analysts at Wedbush in a research report issued on Monday. They presently have a $39.00 price target on the biopharmaceutical company’s stock. Wedbush’s price target would indicate a potential upside of 148.57% from the stock’s current price.

A number of other equities research analysts have also recently commented on LXRX. HC Wainwright set a $27.00 price objective on Lexicon Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 3rd. BidaskClub raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, June 14th. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. Finally, Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $27.00.

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) traded down 1.34% during trading on Monday, hitting $15.48. The company had a trading volume of 159,979 shares. Lexicon Pharmaceuticals has a 12-month low of $13.41 and a 12-month high of $19.62. The stock has a 50-day moving average of $16.60 and a 200 day moving average of $15.38. The stock’s market capitalization is $1.63 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The firm had revenue of $12 million during the quarter, compared to analysts’ expectations of $18.34 million. During the same quarter last year, the firm posted ($0.37) earnings per share. The company’s revenue for the quarter was down 40.3% compared to the same quarter last year. On average, analysts predict that Lexicon Pharmaceuticals will post ($1.49) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/07/lexicon-pharmaceuticals-inc-nasdaqlxrx-earns-ourperform-rating-from-wedbush.html.

Several hedge funds and other institutional investors have recently made changes to their positions in LXRX. C WorldWide Group Holding A S boosted its position in shares of Lexicon Pharmaceuticals by 2.5% in the first quarter. C WorldWide Group Holding A S now owns 11,677 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 280 shares during the last quarter. First Mercantile Trust Co. boosted its position in shares of Lexicon Pharmaceuticals by 11.2% in the second quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 1,227 shares during the last quarter. 361 Capital LLC bought a new position in shares of Lexicon Pharmaceuticals during the first quarter valued at about $186,000. Legal & General Group Plc boosted its position in shares of Lexicon Pharmaceuticals by 2.6% in the second quarter. Legal & General Group Plc now owns 18,570 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 465 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Lexicon Pharmaceuticals during the first quarter valued at about $323,000.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.